News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Policy
Santhera Pharmaceuticals AG Eyes Approval of Lead Drug, Catena in First Half of 2011
June 16, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Reuters -- Swiss Santhera is aiming to seek approval for lead drug Catena to treat a rare eye disease in the first half of 2011 after a trial showed it improved sight, boosting the biotech group's prospects.
Twitter
LinkedIn
Facebook
Email
Print
Regulatory
MORE ON THIS TOPIC
Regulatory
Trump picks White House aide Heidi Overton as FDA chief: Reports
August 19, 2026
·
4 min read
·
Annalee Armstrong
FDA
Amylyx’s redemption story, Summit’s survival woes, Definium’s anxiety win, more
August 19, 2026
·
2 min read
·
Jef Akst
Approvals
BMS welcomes new multiple myeloma drug as generics batter current portfolio
August 14, 2026
·
2 min read
·
Tristan Manalac
Regulatory
Pressure piles on Amgen after EU pulls Tavneos, flags ‘serious breaches’ in pivotal study
August 14, 2026
·
2 min read
·
Tristan Manalac
